Supplementary materials

Table of contents

Text S1: English translation of the questionnaire
Table S1: Characteristics of the invited persons, stratified by participation status
Table S2: Characteristics of participants, stratified by participation 20
Table S3: Risk differences for post-acute symptoms reported after six, nine or twelve months, comparison of SARS-CoV-2 test-positive and test-negative participants 21
Table S5: Risk differences of health problems after 6-12 months, comparing SARS-CoV-2 test-positive and test- negative participants, stratified by sex and age group
Table S6: Risk differences of self-reported diagnoses after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group 31
Table S6: Risk differences of self-reported diagnoses after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued 32
Figure S1: Risk differences of symptoms around the test date, comparing SARS-CoV-2 test-positive and test- negative participants
Figure S2: Risk differences of symptoms 6-12 months after test, comparing hospitalized and non-hospitalized SARS-CoV-2 test-positive participants
Figure S3: Risk differences self-reported health problems with new onset from the test date and up to after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group
Figure S4: Risk differences self-reported diagnoses with new onset from the test date and up to after 6-12 months,

Text S1: English translation of the questionnaire

Background information: This is a print of an electronic questionnaire containing activations. This means that when filling out the questionnaire electronically, it depends on test status and/or answers to previous questions, which questions a given participant will be asked next. In this print, activations will be indicated by explanatory text in square brackets. When send out to participants, their specific test date of reference, were inserted in all places indicated by [*test date*]. In one some questions, the listed time intervals differed depending on whether participants received the questionnaire 6, 9 or 12 month after the test. In this example, the intervals for at 6 months are shown.

[Start page in the questionnaire]

Welcome to the EFTER-COVID baseline questionnaire

In the EFTER-COVID project, we are examining the health of the population during and after the coronavirus pandemic. Your answers are important, regardless of whether you have tested positive or negative for coronavirus (COVID-19)

Everyone invited to participate in the study has been randomly selected to receive a questionnaire with a particular focus on a certain area of their health. The questionnaire you have received focuses on physical symptoms.

Many thanks for your help.

[Test-positive participants only]:

These first questions are about how you have been since you tested positive at [testdate]

Which of the following conditions best describes how you were when you were at your worst?

Think about the period from a week before you tested positive until 4 weeks after.

- (1) \Box I had no symptoms
- (2) \Box I was ill at home
- (3) \Box I was hospitalised due to COVID-19
- (4) \Box I was hospitalised due to COVID-19 and was intubated with a ventilator
- (5) \Box I was hospitalised for reasons other than COVID-19

[*Test-positive participants only*]:

Did you take any of the following types of medication for your COVID-19 symptoms?

Think of the period from one week before you were tested at [test date] and until 4 weeks after.

- (1) \Box Painkillers/antipyretics
- (2) \Box Asthma medication
- (3) \Box Other please specify _____
- (4) \Box I didn't take any medication

[Test-negative participants only]:

Why were you tested on the [test date]?

- (1) \Box I had symptoms
- (2) \Box I was a close contact of someone infected
- (3) \Box I suspected that I had been exposed to the infection
- (4) \Box Other
- (5) \Box I can't remember

Physical symptoms in the period around the test.

Have you at any point had any of the following symptoms? Please consider the period from the week leading up to your test on [*test date*] and until now.

Kindly mark all the symptoms you have had without considering the symptom cause. You can add further comments at the end of the questionnaire.

	Yes	No	Don't know
Fever	(1)	(0)	(99)
Chills	(1)	(0)	(99)
Hot flushes / sweating	(1)	(0)	(99)
Headache	(1)	(0)	(99)
Muscle or joint pain	(1)	(0)	(99)
Fatigue or exhaustion	(1)	(0)	(99)
Dizziness	(1)	(0)	(99)
Red or watery eyes	(1)	(0)	(99)
Runny or stuffy nose	(1)	(0)	(99)

Continued from previous page: In the week leading up to the test on [*test date*], and until now, did you have any of the following symptoms?

Kindly mark all the symptoms you have had without considering the symptom cause. You can add further comments at the end of the questionnaire.

	Yes	No	Don't know
Reduced or altered sense of smell	(1)	(0)	(99)
Reduced or altered sense of taste	(1)	(0)	(99)
Cough	(1)	(0)	(99)
Sore throat or pain when swallowing	(1)	(0)	(99)
Shortness of breath	(1)	(0)	(99)
Chest pain	(1)	(0)	(99)
Nausea or vomiting	(1)	(0)	(99)
Diarrhoea	(1)	(0)	(99)
Abdominal pain	(1)	(0)	(99)
Reduced or loss of appetite	(1)	(0)	(99)
Reduced arm and leg strength	(1)	(0)	(99)
Sleeping or tingling sensation, or other abnormal sensations in the legs and arms	(1)	(0)	(99)
Other symptoms	(1)	(0)	(99)

[In this question, only lines related to symptoms, which the participants have replied "yes" to in the previous question are displayed]

During which periods did you have symptoms?

"Around the test date" covers the period from a week before the test on [test date] and up to four weeks after.

Please mark all of the periods during which you have had the symptom. If you have trouble remembering, then please mark the periods to the best of your ability.

	Around the test date	1-2 months following the test	2-6 months following the test	The past 14 days
Fever	(1)	(12)	(26)	(14)
Chills	(1)	(12)	(26)	(14)
Hot flushes / sweating	(1)	(12)	(26)	(14)
Headache	(1)	(12)	(26)	(14)
Muscle or joint pain	(1)	(12)	(26)	(14)
Fatigue or exhaustion	(1)	(12)	(26)	(14)
Dizziness	(1)	(12)	(26)	(14)
Red or watery eyes	(1)	(12)	(26)	(14)
Runny or stuffy nose	(1)	(12)	(26)	(14)
Reduced or altered sense of smell	(1)	(12)	(26)	(14)

Reduced or altered sense of taste	(1)	(12)	(26)	(14)
Sore throat or pain when swallowing	(1)	(12)	(26)	(14)
Cough	(1)	(12)	(26)	(14)
Shortness of breath	(1)	(12)	(26)	(14)
Chest pain	(1)	(12)	(26)	(14)
Nausea or vomiting	(1)	(12)	(26)	(14)
Diarrhoea	(1)	(12)	(26)	(14)
Abdominal pain	(1)	(12)	(26)	(14)
Reduced or loss of appetite	(1)	(12)	(26)	(14)
Reduced arm and leg strength	(1)	(12)	(26)	(14)
Sleeping or tingling sensation, or other abnormal sensations in the legs and arms	(1)	(12)	(26)	(14)

[Only participants, who replied "yes" to having had fever]:

Did you take your temperature when you had a fever in the period around your test on the [test date]?

- (1) \Box Yes (please write the highest temperature taken in the box below) _____
- (0) 🗌 No
- (99) 🗌 Don't know/Can't remember

[Only participants, who replied "yes" to having had fever]:

Were there known/probable causes other than COVID-19 for you having a fever in the period around the test on *[test date]*?

- (1) \Box Yes (please explain in the box below) _____
- (0) 🗆 No
- (99) \Box Don't know

[In this question, only lines related to symptoms, which the participants have replied "yes" to having experienced, will be displayed]

Before the test on [*test date*], did you generally (i.e. often or chronically) suffer from any of the following physical symptoms?

	Yes	No	Don't know
Fever	(1)	(0)	(99)
Chills	(1)	(0)	(99)
Hot flushes / sweating	(1)	(0)	(99)
Headache	(1)	(0)	(99)
Muscle or joint pain	(1)	(0)	(99)
Fatigue or exhaustion	(1)	(0)	(99)
Dizziness	(1)	(0)	(99)
Red or watery eyes	(1)	(0)	(99)

Runny or stuffy nose	(1)	(0)	(99)	
Reduced or altered sense of smell	(1)	(0)	(99)	
Reduced or altered sense of taste	(1)	(0)	(99)	
Sore throat or pain when swallowing	(1)	(0)	(99)	
Cough	(1)	(0)	(99)	
Shortness of breath	(1)	(0)	(99)	
Chest pain	(1)	(0)	(99)	
Nausea or vomiting	(1)	(0)	(99)	
Diarrhoea	(1)	(0)	(99)	
Abdominal pain	(1)	(0)	(99)	
Reduced or loss of appetite	(1)	(0)	(99)	
Reduced arm and leg strength	(1)	(0)	(99)	
Sleeping or tingling sensation, or other abnormal sensations in the legs and arms	(1)	(0)	(99)	

[Only participants, who replied "yes" to having had headache. Only lines representing time intervals, where participants indicated having headache are displayed]:

How severe were your headaches when you were at your worst during the specified period(s)?

	No pain	Mild pain	Moderate pain	Strong pain	Unbearable pain
Generally before the test date	(1)	(2)	(3)	(4)	(5)
Around the test date	(1)	(2)	(3)	(4)	(5)
1-2 months following the test	(1)	(2)	(3)	(4)	(5)
2-6 months following the test	(1)	(2)	(3)	(4)	(5)
The past 14 days	(1)	(2)	(3)	(4)	(5)

[Only participants, who replied "yes" to having had muscle or joint pain. Only lines representing time intervals, where participants indicated having this are displayed]:

How bad was your muscle or joint pain in the specified period(s)?

	No pain	Mild pain	Moderate pain	Strong pain	Unbearable pain
Generally before the test date	(1)	(2)	(3)	(4)	(5)
Around the test date	(1)	(2)	(3)	(4)	(5)
1-2 months following the test	(1)	(2)	(3)	(4)	(5)
2-6 months following the test	(1)	(2)	(3)	(4)	(5)
The past 14 days	(1)	(2)	(3)	(4)	(5)

[Only participants, who replied "yes" to having had reduced or changed sense of smell. Only lines representing time intervals, where participants indicated having this are displayed]:

How was your sense of smell in the specified period(s), compared to normal?

My sense of smell was/is...

	Slightly reduced	Very reduced	Completely gone	Changed	Don't know
Generally before the test date	(1)	(2)	(3)	(4)	(5)
Around the test date	(1)	(2)	(3)	(4)	(5)
1-2 months following the test	(1)	(2)	(3)	(4)	(5)
2-6 months following the test	(1)	(2)	(3)	(4)	(5)
The past 14 days	(1)	(2)	(3)	(4)	(5)

[Only participants, who replied "yes" to having had reduced or changed sense of taste. Only lines representing time intervals, where participants indicated having this are displayed]:

How was your sense of taste in the specified period(s), compared to normal?

My sense of taste was/is...

	Slightly reduced	Very reduced	Completely gone	Changed	Don't know
Generally before the test date	(1)	(2)	(3)	(4)	(5)
Around the test date	(1)	(2)	(3)	(4)	(5)
1-2 months following the test	(1)	(2)	(3)	(4)	(5)

2-6 months following the test	(1)	(2)	(3)	(4)	(5)
The past 14 days	(1)	(2)	(3)	(4)	(5)

[Only participants, who replied "yes" to having experienced shortness of breath. Only lines representing time intervals, where participants indicated having this are displayed]:

Choose the following statement below that best describes your shortness of breath during the relevant period(s).

A. I only become short of breath when I exert myself a lot

B. I become short of breath when I hurry or walk up a small hill

C. I walk slower than others my age due to my shortness of breath, or I have to stop to catch my breath when walking on even terrain

D. I stop to catch my breath after about 100 metres or a few minutes of walking

E. I have too much shortness of breath to leave my home, or I get short of breath when getting (un)dressed

	А	В	С	D	E	Don't know
Generally before the test date	(1)	(2)	(3)	(4)	(5)	(99)
Around the test date	(1)	(2)	(3)	(4)	(5)	(99)
1-2 months following the test	(1)	(2)	(3)	(4)	(5)	(99)
2-6 months following the test	(1)	(2)	(3)	(4)	(5)	(99)
In the past 14 days	(1)	(2)	(3)	(4)	(5)	(99)

[Only participants indicating having had other symptoms]:

Which other symptoms have you had and when?

[Only participants indicating having had other symptoms]:

Did you also used to have these symptoms generally (i.e. chronically or often) before the test on [test date]?

[test-positives only]:

Did your health return to normal within 4 weeks of testing positive for COVID-19?

(0) \Box No, my health at this time was not yet completely back to as it was before I became ill

(1) \Box Yes, my health returned to normal a number of days after symptoms started (write the number of days in the field below) _____

(99) 🗌 Don't know

Did you take sick leave around the time of the test on [test date], or any time since then?

Please mark all of the relevant answers, regardless of the cause of illness

- (1) \Box Yes, I was on sick leave in the week up to the test or up to 4 weeks after
- (2) \Box Yes, I was on sick leave more than 4 weeks after the test
- (0) 🗌 No
- (3) \Box Not relevant

[Only shown for participants, who indicated taking sick leave around the test date]:

How long were you on sick leave in the period around the test?

Think about the period from one week before the test on [test date] and up to 4 weeks after.

Please write the number of <u>sick days</u> in the box below. If you can't remember the exact number, write an approximate amount of days. Have you not been on sick leave, please write '0' in the boxes below.

Full-time sick leave:

Part-time sick leave:

[Only shown for participants, who indicated taking sick leave later than 4 weeks after the test date]:

If you were on sick leave later than 4 weeks after the test date, were you on full-time or part-time sick leave?

If you have been on both full-time and part-time sick leave, please mark both answers below

- (1) \Box Full-time sick leave
- (2) \Box Part-time sick leave

[test-positives only]:

Was your sick leave related to you having had COVID-19?

- (1) \Box Yes
- (0) 🗆 No
- (2) \Box Partly
- (99) 🗌 Don't know

[Only participants, who indicated having been on full-time sick leave]:

How long were you on full-time sick leave?

- (2) \Box Less than 2 weeks
- (4) \Box 2-4 weeks
- (12) \Box 1-2 months
- (24) \Box 2-4 months
- $(46) \quad \Box \ 4-6 \ months$
- (10,000) \Box I have been on full-time sick leave since the test date

[Only participants, who indicated having been on part-time sick leave]:

How long were you on part-time sick leave?

- (2) \Box Less than 2 weeks
- (4) \Box 2-4 weeks
- (12) \Box 1-2 months
- (24) \Box 2-4 months
- (46) \Box 4-6 months
- (10,000) \Box I have been on part-time sick leave since the test date

[Only participants, who replied indicated having been on sick leave]:

Has any of your sick leave been within the past 14 days?

- (1) \Box Yes
- (0) 🗌 No
- (3) \Box Not relevant

The following pages contain some background questions about your health, education, work and lifestyle.

Please provide your height in cm

If you don't know your height, or do not wish to answer, please click "Next" below.

Please provide your approximate weight in kg.

If you don't know your weight, or do not wish to answer, please click "Next" below

What is your highest level of education?

- (1) \Box Primary/Elementary school (9th–10th grade)
- (2) \Box General secondary education or vocational secondary education
- (3) \Box Vocational training
- (4) \Box Shorter term higher education (1–2 years), e.g. vocational academy
- (5) 🗌 Medium term higher education (2–4 years), e.g. nursing, primary school teaching, BSc
- (6) Longer term higher education (more than 5 years), e.g. Masters or PhD
- (99) \Box Don't know/None of the above/Do not wish to answer

What is your main occupational status?

- (1) \Box Employed full-time
- (2) \Box Employed part-time
- (3) \Box Self-employed
- (4) \Box Student
- (5) \Box Stay-at-home parent or on parental leave
- (6) \Box Jobseeking/Unemployed
- (7) \Box Benefits recipient
- (8) \Box Long-term sick leave
- (9) \Box Pensioner or early retiree
- (10) \Box Other

Do you smoke or have you previously smoked?

- (1) \Box I've never smoked
- (2) \Box It has been more than 5 years since I smoked
- (3) \Box I have smoked within the past 5 years, but no longer smokes
- (4) \Box I smoke occasionally, e.g. social events
- (5) \Box I smoke daily (fewer than 10 cigarettes/cigars/pipes per day)
- (6) \Box I smoke daily (10 or more cigarettes/cigars/pipes per day)
- (7) \Box I smoke e-cigarettes/I vape

Please indicate how many alcoholic drinks you have on average per week.

One drink is for example 1 beer (330ml), 1 glass of wine (120ml), 1 glass of fortified wine (80ml), or 1 shot of spirits (40ml).

If you don't know, or don't wish to answer, please click "Next" below.

If you look at the six months before the test on [*test date*], what would you say best describes your level of physical activity in your spare time?

- (1) \Box Train hard and play competitive sports regularly, several times a week
- (2) \Box Work out or do heavy gardening or similar at least 4 times a week
- (3) \Box Walk, cycle or other light exercise at least 4 times a week (including leisure walks, light gardening, and cycling/walking to work)
- (4) \Box Read, watch TV or other sedentary lifestyle

If you look at the six months before the test on [test date], how would you describe your physical fitness?

- (1) \Box Really good
- (2) 🗌 Good
- (3) 🗌 Fair
- (4) \Box Less good
- (5) \Box Poor

In the period six months before the test on [*test date*] and up to now, have you had any of the following problems?

Please mark all the relevant answers

	Yes, before the test date	Yes, after the test date	No	Don't know
Difficulties concentrating	(1)	(2)	(0)	(99)
Issues with memory	(1)	(2)	(0)	(99)
Mental exhaustion	(1)	(2)	(0)	(99)
Physical exhaustion	(1)	(2)	(0)	(99)
Sleep problems	(1)	(2)	(0)	(99)

Have you ever been diagnosed by a doctor with any of the following conditions?

	Yes, before the test date	Yes, after the test date	No
Depression	(1)	(2)	(0)
Anxiety	(1)	(2)	(0)
PTSD (Post traumatic stress disorder)	(1)	(2)	(0)
Chronic fatigue syndrome	(1)	(2)	(0)
Fibromyalgia	(1)	(2)	(0)

Before the test on [test date], were you diagnosed with any chronic disease(s)?

Please mark all relevant.

- (1) \Box No known chronic diseases
- (2) \Box Diabetes
- (3) \Box Asthma
- (4) \Box High blood pressure
- (5) \Box COPD or other chronic lung disease
- (6) \Box Chronic or frequent headaches, including migraines
- (7) \Box Other chronic diseases
- (8) \Box Do not wish to respond

[Test-negatives only]:

Do you think that you have ever had covid-19?

- (1) \Box Yes
- (0) 🗌 No
- (99) 🗌 Don't know

[Test-negatives, replying yes to the previous question]:

Why do you think you probably had covid-19?

Please mark all relevant.

- (1) \Box Antibodies were detected in my blood sample
- (2) \Box I had symptoms and I think it was covid-19
- (3) \Box I had symptoms, and talked to a doctor who thought it was covid-19
- (4) \Box For other reasons

Many thanks for taking the time to complete our questionnaire.

May we contact you again?

- (1) \Box Yes
- (0) 🗌 No

If you have any further comments, feel free to write them in the box below.

Please, remember to click "Finish"

18

	Positive	Negative	p-value
Age group (n,%)			
15-19	2350 (3.9%)	3181 (3.5%)	< 0.0001
20-29	9021 (14.8%)	8958 (9.7%)	
30-39	7979 (13.1%)	9838 (10.7%)	
40-49	11 377 (18.7%)	16 117 (17.5%)	
50-59	14 946 (24.5%)	23 873 (26.0%)	
60-69	9530 (15.6%)	18 975 (20.7%)	
70+	5799 (9.5%)	10 936 (11.9%)	
Obesity (n,%)			
Non-obese	46 256 (75.8%)	68 712 (74.8%)	< 0.0001
Obese	9973 (16.3%)	15 073 (16.4%)	
No information	4773 (7.8%)	8093 (8.8%)	
Charlson comorbidity score (n,%)			
0	53 530 (87.8%)	78 694 (85.7%)	< 0.0001
1	3807 (6.2%)	6309 (6.9%)	
2 or more	3665 (6.0%)	6875 (7.4%)	
Region (n, %)			
Hovedstaden	26 242 (43.0%)	29 768 (32.4%)	< 0.000
Midtjylland	11 233 (18.4%)	19 737 (21.5%)	
Syddanmark	9557 (15.7%)	19 134 (20.8%)	
Sjælland	9233 (15.1%)	12 678 (13.8%)	
Nordjylland	4706 (7.7%)	10 504 (11.4%)	
No information	31 (0.1%)	57 (0.1%)	
Origin (n, %)			
Danish	52 622 (86.3%)	84 045 (91.5%)	< 0.0001
Born abroad	7122 (11.7%)	7165 (7.8%)	
Immigrant	1257 (2.1%)	665 (0.7%)	
Comorbidities (n, %)			
Diabetes	2647 (4.3%)	4202 (4.6%)	0.03
Asthma	4579 (7.5%)	6167 (6.7%)	< 0.000
High blood pressure	8842 (14.5%)	14 903 (16.2%)	< 0.000
COPD or other chronic lung disease	1187 (1.9%)	2453 (2.7%)	< 0.000
Chronic headache (including migraine)	2138 (3.5%)	3457 (3.8%)	0.0
Other chronic disease	7968 (13.1%)	14 751 (16.1%)	< 0.000
Occupation (n, %)			
Non-healthcare worker	54 400 (89.2%)	79 654 (86.7%)	< 0.000
	6602 (10.8%)		. 5.000

Table S1: Characteristics of the invited persons, stratified by participation status

	Non-participants	Full-participants	Partial- participants	p-value
Test result (n,%)	* *	. .	A A	*
Negative	154 085 (59.1%)	91 878 (60.1%)	11 687 (72.5%)	< 0.0001
Positive	106 552 (40.9%)	61 002 (39.9%)	4438 (27.5%)	
Sex (n, %)				
Female	133 489 (51.2%)	93 494 (61.2%)	10 246 (63.5%)	< 0.0001
Male	127 148 (48.8%)	59 386 (38.8%)	5879 (36.5%)	
Age group (n,%)				
15-19	33 372 (12.8%)	5531 (3.6%)	1757 (10.9%)	< 0.0001
20-29	68 006 (26.1%)	17 979 (11.8%)	3025 (18.8%)	
30-39	50 752 (19.5%)	17 817 (11.7%)	2621 (16.3%)	
40-49	47 302 (18.1%)	27 494 (18.0%)	2825 (17.5%)	
50-59	35 868 (13.8%)	38 819 (25.4%)	2866 (17.8%)	
60-69	15 522 (6.0%)	28 505 (18.6%)	1694 (10.5%)	
70+	9815 (3.8%)	16 735 (10.9%)	1337 (8.3%)	
Occupation (n,%)				
Non-healthcare worker	239 173 (91.8%)	134 054 (87.7%)	14 551 (90.2%)	< 0.0001
Healthcare worker	21 464 (8.2%)	18 826 (12.3%)	1574 (9.8%)	
Elderly home (n,%)				
No	258 830 (99.3%)	152 665 (99.9%)	16 060 (99.6%)	< 0.0001
Yes	1807 (0.7%)	215 (0.1%)	65 (0.4%)	
Origin (n,%)				
Danish	198 669 (76.2%)	136 667 (89.4%)	13 097 (81.2%)	< 0.0001
Born abroad	47 158 (18.1%)	14 287 (9.3%)	2536 (15.7%)	
Immigrant	14 797 (5.7%)	1922 (1.3%)	490 (3.0%)	
Region (n,%)				
Hovedstaden	108 575 (41.7%)	56 010 (36.6%)	6216 (38.5%)	< 0.0001
Midtjylland	50 097 (19.2%)	30 970 (20.3%)	3293 (20.4%)	
Nordjylland	23 400 (9.0%)	15 210 (9.9%)	1580 (9.8%)	
Sjælland	33 807 (13.0%)	21 911 (14.3%)	2094 (13.0%)	
Syddanmark	44 522 (17.1%)	28 691 (18.8%)	2933 (18.2%)	
NA	236 (0.1%)	88 (0.1%)	9 (0.1%)	
Hospitalization due to COVID-19 n,%)				
No	257 488 (98.8%)	150 379 (98.4%)	15 814 (98.1%)	< 0.0001
Yes	3149 (1.2%)	2501 (1.6%)	311 (1.9%)	

Note: Charlson comorbidity scores were based on data from the Danish National Patient Register, whereas the listed comorbidities were self-reported.

Table S3: Risk differences for post-acute symptoms reported after six, nine or twelve months, comparison of SARS-CoV-2 test-positive and test-negative participants

	6 months after test (n = 22 541)			9 months after test (n = 106 611)			12 months after test $(n = 23728)$		
Symptom	Positive (n,%)	Negative (n,%)	RD (95% CI)	Positive (n,%)	Negative (n,%)	RD (95% CI)	Positive (n,%)	Negative (n,%)	RD (95% CI)
Dysosmia	702 (9.4%)	70 (0.5%)	9.38 (8.66, 10.20)	5044 (11.5%)	422 (0.7%)	11.56 (11.24, 11.89)	928 (9.5%)	112 (0.8%)	9.26 (8.61, 9.92)
Dysgeusia	587 (7.8%)	59 (0.4%)	7.78 (7.13, 8.44)	4008 (9.2%)	391 (0.6%)	9.06 (8.76, 9.36)	770 (7.9%)	101 (0.7%)	7.65 (7.05, 8.28)
Fatigue/exhaustion	920 (12.3%)	435 (2.9%)	9.79 (8.92, 10.66)	4905 (11.2%)	1959 (3.1%)	8.49 (8.14, 8.86)	974 (9.9%)	474 (3.4%)	6.95 (6.24, 7.77)
Dyspnea	450 (6.0%)	122 (0.8%)	5.70 (5.09, 6.29)	2361 (5.4%)	556 (0.9%)	4.86 (4.61, 5.12)	466 (4.8%)	135 (1.0%)	4.19 (3.73, 4.69)
Reduced strength legs/arms	448 (6.0%)	140 (0.9%)	5.21 (4.57, 5.83)	2448 (5.6%)	715 (1.1%)	4.71 (4.46, 5.00)	485 (5.0%)	169 (1.2%)	4.04 (3.53, 4.58)
Sleeping legs/arms	355 (4.7%)	174 (1.2%)	3.67 (3.12, 4.23)	2053 (4.7%)	859 (1.4%)	3.53 (3.29, 3.78)	433 (4.4%)	203 (1.5%)	3.21 (2.68, 3.74)
Muscle/joint pain	429 (5.7%)	263 (1.7%)	4.05 (3.44, 4.73)	2304 (5.3%)	1236 (2.0%)	3.41 (3.15, 3.67)	484 (4.9%)	273 (2.0%)	3.17 (2.64, 3.75)
Headache	502 (6.7%)	413 (2.7%)	4.05 (3.36, 4.79)	2657 (6.1%)	2003 (3.2%)	2.93 (2.63, 3.25)	581 (5.9%)	452 (3.2%)	2.69 (2.11, 3.30)
Dizziness	322 (4.3%)	210 (1.4%)	2.86 (2.33, 3.45)	1754 (4.0%)	1049 (1.7%)	2.38 (2.15, 2.61)	354 (3.6%)	236 (1.7%)	1.91 (1.45, 2.42)
Chest pain	234 (3.1%)	90 (0.6%)	2.54 (2.13, 3.00)	1195 (2.7%)	538 (0.9%)	1.97 (1.79, 2.15)	266 (2.7%)	152 (1.1%)	1.72 (1.34, 2.13)
Hot flushes/sweat	264 (3.5%)	225 (1.5%)	2.04 (1.52, 2.57)	1474 (3.4%)	1085 (1.7%)	1.63 (1.42, 1.85)	309 (3.2%)	240 (1.7%)	1.49 (1.03, 1.99)
Reduced appetite	242 (3.2%)	153 (1.0%)	2.08 (1.64, 2.54)	1251 (2.9%)	815 (1.3%)	1.45 (1.26, 1.65)	279 (2.8%)	208 (1.5%)	1.32 (0.90, 1.75)
Chills	117 (1.6%)	134 (0.9%)	0.51 (0.18, 0.85)	702 (1.6%)	666 (1.1%)	0.48 (0.33, 0.63)	147 (1.5%)	180 (1.3%)	0.15 (-0.20, 0.49)
Red runny eyes	92 (1.2%)	97 (0.6%)	0.58 (0.30, 0.91)	583 (1.3%)	512 (0.8%)	0.48 (0.34, 0.61)	147 (1.5%)	139 (1.0%)	0.56 (0.26, 0.92)
Nausea	136 (1.8%)	166 (1.1%)	0.59 (0.22, 0.98)	846 (1.9%)	915 (1.5%)	0.41 (0.25, 0.59)	197 (2.0%)	213 (1.5%)	0.42 (0.04, 0.80)
Abdominal pain	156 (2.1%)	192 (1.3%)	0.83 (0.41, 1.25)	877 (2.0%)	1005 (1.6%)	0.35 (0.18, 0.54)	208 (2.1%)	213 (1.5%)	0.51 (0.13, 0.89)
Diarrhoea	119 (1.6%)	190 (1.3%)	0.23 (-0.11, 0.57)	830 (1.9%)	962 (1.5%)	0.32 (0.14, 0.51)	173 (1.8%)	186 (1.3%)	0.53 (0.17, 0.88)
Fever	172 (2.3%)	206 (1.4%)	0.69 (0.28, 1.13)	978 (2.2%)	1120 (1.8%)	0.27 (0.07, 0.47)	212 (2.2%)	258 (1.9%)	0.15 (-0.24, 0.56)
Cough	349 (4.6%)	592 (3.9%)	0.34 (-0.25, 0.96)	2097 (4.8%)	2789 (4.4%)	-0.02 (-0.29, 0.25)	510 (5.2%)	696 (5.0%)	-0.25 (-0.95, 0.36)
Runny nose	267 (3.6%)	527 (3.5%)	-0.26 (-0.80, 0.27)	1710 (3.9%)	2373 (3.8%)	-0.16 (-0.44, 0.09)	399 (4.1%)	574 (4.1%)	-0.41 (-0.96, 0.19)
Sore throat	276 (3.7%)	519 (3.5%)	-0.16 (-0.75, 0.45)	1602 (3.7%)	2583 (4.1%)	-0.79 (-1.04, -0.52)	404 (4.1%)	588 (4.2%)	-0.47 (-1.09, 0.17)

(page 1 of 7)

	Female (n = 93 494)			Male (n = 59 386)			
Symptom	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Abdominal pain	15-19	49 (3.2%)	69 (3.2%)	0.08 (-1.21, 1.45)	9 (1.1%)	22 (2.2%)	-1.25 (-2.54, 0.09)
	20-29	179 (3.0%)	198 (3.2%)	-0.09 (-0.74, 0.55)	55 (1.8%)	40 (1.5%)	0.34 (-0.38, 1.08)
	30-39	162 (3.3%)	216 (3.3%)	0.03 (-0.61, 0.74)	56 (1.9%)	51 (1.6%)	0.34 (-0.35, 1.06)
	40-49	180 (2.6%)	218 (2.0%)	0.55 (0.10, 1.02)	69 (1.6%)	72 (1.4%)	0.24 (-0.27, 0.76)
	50-59	226 (2.6%)	251 (1.6%)	0.99 (0.62, 1.38)	72 (1.1%)	70 (0.8%)	0.29 (-0.01, 0.62)
	60-69	98 (1.9%)	107 (1.0%)	0.91 (0.51, 1.30)	44 (1.0%)	44 (0.6%)	0.39 (0.09, 0.69)
	70+	23 (0.8%)	30 (0.6%)	0.22 (-0.13, 0.60)	19 (0.6%)	22 (0.4%)	0.21 (-0.06, 0.53)
Dyspnea	15-19	53 (3.5%)	34 (1.6%)	2.37 (1.09, 3.65)	13 (1.6%)	10 (1.0%)	0.71 (-0.54, 1.94)
	20-29	252 (4.3%)	80 (1.3%)	3.48 (2.81, 4.16)	84 (2.7%)	23 (0.9%)	2.22 (1.40, 2.97)
	30-39	305 (6.1%)	77 (1.2%)	5.35 (4.60, 6.10)	123 (4.1%)	23 (0.7%)	3.77 (2.98, 4.63)
	40-49	509 (7.2%)	117 (1.1%)	6.25 (5.61, 6.90)	250 (5.8%)	48 (0.9%)	5.08 (4.37, 5.89)
	50-59	614 (7.2%)	171 (1.1%)	5.94 (5.37, 6.51)	376 (5.9%)	71 (0.8%)	4.98 (4.36, 5.55)
	60-69	303 (6.0%)	68 (0.6%)	5.04 (4.44, 5.68)	235 (5.3%)	49 (0.6%)	4.30 (3.67, 4.95)
	70+	76 (2.7%)	22 (0.4%)	2.10 (1.49, 2.68)	84 (2.8%)	20 (0.4%)	2.22 (1.64, 2.79)
Chest pain	15-19	57 (3.8%)	32 (1.5%)	2.62 (1.43, 3.98)	14 (1.7%)	10 (1.0%)	0.78 (-0.38, 2.05)
	20-29	214 (3.6%)	85 (1.4%)	2.57 (1.97, 3.21)	69 (2.2%)	29 (1.1%)	1.30 (0.48, 2.01)
	30-39	182 (3.7%)	75 (1.1%)	2.79 (2.13, 3.50)	85 (2.8%)	41 (1.3%)	1.74 (1.00, 2.52)
	40-49	279 (4.0%)	127 (1.2%)	2.90 (2.36, 3.41)	107 (2.5%)	42 (0.8%)	1.72 (1.19, 2.28)
	50-59	286 (3.3%)	133 (0.9%)	2.46 (2.06, 2.89)	154 (2.4%)	59 (0.7%)	1.64 (1.26, 2.05)
	60-69	104 (2.1%)	68 (0.6%)	1.35 (0.97, 1.75)	87 (1.9%)	48 (0.6%)	1.20 (0.81, 1.61)
	70+	24 (0.8%)	13 (0.2%)	0.53 (0.24, 0.86)	33 (1.1%)	18 (0.3%)	0.67 (0.34, 1.03)

(page 2 of 7)

			Female (n = 93 494))		Male (n = 59 386)	
Symptom	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Chills	15-19	41 (2.7%)	45 (2.1%)	0.72 (-0.53, 1.85)	6 (0.7%)	16 (1.6%)	-0.96 (-2.04, 0.04)
	20-29	140 (2.4%)	127 (2.0%)	0.41 (-0.17, 1.01)	37 (1.2%)	35 (1.3%)	-0.11 (-0.80, 0.53)
	30-39	122 (2.5%)	141 (2.1%)	0.35 (-0.22, 0.96)	52 (1.7%)	59 (1.8%)	-0.07 (-0.77, 0.61)
	40-49	147 (2.1%)	156 (1.4%)	0.65 (0.23, 1.08)	51 (1.2%)	57 (1.1%)	0.10 (-0.34, 0.52)
	50-59	164 (1.9%)	173 (1.1%)	0.78 (0.45, 1.10)	76 (1.2%)	53 (0.6%)	0.54 (0.25, 0.85)
	60-69	46 (0.9%)	60 (0.5%)	0.34 (0.08, 0.62)	43 (1.0%)	29 (0.4%)	0.54 (0.25, 0.84)
	70+	22 (0.8%)	17 (0.3%)	0.41 (0.09, 0.77)	19 (0.6%)	12 (0.2%)	0.37 (0.10, 0.66)
Cough	15-19	152 (10.1%)	244 (11.3%)	-1.32 (-3.49, 0.80)	55 (6.6%)	100 (9.8%)	-3.49 (-6.02, -0.92)
	20-29	399 (6.8%)	540 (8.6%)	-1.86 (-2.85, -0.89)	181 (5.8%)	180 (6.7%)	-0.92 (-2.22, 0.42)
	30-39	273 (5.5%)	387 (5.9%)	-0.36 (-1.21, 0.49)	169 (5.6%)	171 (5.2%)	0.41 (-0.73, 1.58)
	40-49	363 (5.2%)	590 (5.5%)	-0.33 (-1.00, 0.34)	171 (3.9%)	247 (4.6%)	-0.73 (-1.57, 0.14)
	50-59	441 (5.2%)	642 (4.2%)	0.98 (0.41, 1.54)	261 (4.1%)	277 (3.3%)	0.76 (0.16, 1.37)
	60-69	204 (4.0%)	316 (2.8%)	1.15 (0.52, 1.74)	117 (2.6%)	196 (2.5%)	0.10 (-0.43, 0.68)
	70+	89 (3.2%)	102 (1.9%)	1.19 (0.45, 1.92)	81 (2.7%)	85 (1.5%)	1.15 (0.52, 1.79)
Diarrhoea	15-19	31 (2.1%)	40 (1.8%)	0.25 (-0.79, 1.32)	13 (1.6%)	19 (1.9%)	-0.36 (-1.75, 0.90)
	20-29	136 (2.3%)	158 (2.5%)	-0.19 (-0.84, 0.40)	55 (1.8%)	44 (1.6%)	0.18 (-0.57, 0.91)
	30-39	147 (3.0%)	183 (2.8%)	0.22 (-0.48, 0.85)	69 (2.3%)	48 (1.5%)	0.91 (0.15, 1.64)
	40-49	166 (2.4%)	177 (1.6%)	0.73 (0.31, 1.20)	65 (1.5%)	89 (1.7%)	-0.19 (-0.71, 0.31)
	50-59	199 (2.3%)	218 (1.4%)	0.89 (0.53, 1.28)	80 (1.2%)	82 (1.0%)	0.27 (-0.08, 0.60)
	60-69	74 (1.5%)	128 (1.1%)	0.28 (-0.05, 0.64)	43 (1.0%)	75 (1.0%)	0.00 (-0.30, 0.32)
	70+	25 (0.9%)	39 (0.7%)	0.13 (-0.23, 0.53)	19 (0.6%)	38 (0.7%)	-0.04 (-0.35, 0.29)

(page 3 of 7)

			Female (n = 93 494	4)		Male (n = 59 386)	
Symptom	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Dizziness	15-19	84 (5.6%)	75 (3.5%)	2.38 (0.84, 3.99)	12 (1.4%)	24 (2.4%)	-1.03 (-2.48, 0.30)
	20-29	305 (5.2%)	218 (3.5%)	1.92 (1.09, 2.69)	70 (2.2%)	55 (2.1%)	0.25 (-0.61, 1.00)
	30-39	321 (6.5%)	197 (3.0%)	3.74 (2.83, 4.61)	98 (3.2%)	55 (1.7%)	1.70 (0.87, 2.55)
	40-49	400 (5.7%)	226 (2.1%)	3.68 (3.05, 4.29)	140 (3.2%)	65 (1.2%)	2.05 (1.42, 2.67)
	50-59	438 (5.1%)	260 (1.7%)	3.42 (2.87, 3.94)	160 (2.5%)	79 (0.9%)	1.53 (1.11, 1.94)
	60-69	164 (3.2%)	119 (1.1%)	2.06 (1.56, 2.58)	108 (2.4%)	52 (0.7%)	1.62 (1.17, 2.07)
	70+	64 (2.3%)	33 (0.6%)	1.51 (0.98, 2.05)	66 (2.2%)	37 (0.7%)	1.38 (0.88, 1.90)
Fatigue/exhaustion	15-19	179 (11.8%)	108 (5.0%)	7.37 (5.41, 9.49)	53 (6.3%)	46 (4.5%)	1.98 (-0.32, 4.25)
	20-29	651 (11.1%)	339 (5.4%)	5.99 (5.00, 7.02)	215 (6.9%)	125 (4.7%)	2.41 (1.13, 3.72)
	30-39	764 (15.4%)	310 (4.7%)	10.93 (9.74, 12.11)	277 (9.2%)	123 (3.8%)	5.61 (4.37, 6.85)
	40-49	1061 (15.1%)	459 (4.3%)	10.84 (9.94, 11.79)	510 (11.8%)	208 (3.9%)	7.93 (6.84, 9.12)
	50-59	1218 (14.3%)	501 (3.2%)	10.91 (10.11, 11.74)	692 (10.8%)	216 (2.6%)	8.17 (7.28, 8.92)
	60-69	525 (10.4%)	212 (1.9%)	8.29 (7.47, 9.15)	359 (8.0%)	118 (1.5%)	6.35 (5.56, 7.19)
	70+	149 (5.3%)	52 (1.0%)	4.24 (3.41, 5.09)	146 (4.9%)	51 (0.9%)	3.92 (3.10, 4.75)
Fever	15-19	59 (3.9%)	98 (4.5%)	-0.66 (-2.01, 0.83)	24 (2.9%)	31 (3.0%)	-0.19 (-1.86, 1.53)
	20-29	225 (3.8%)	240 (3.8%)	0.03 (-0.72, 0.73)	75 (2.4%)	78 (2.9%)	-0.51 (-1.37, 0.31)
	30-39	157 (3.2%)	200 (3.0%)	0.14 (-0.49, 0.82)	90 (3.0%)	73 (2.2%)	0.82 (-0.01, 1.66)
	40-49	169 (2.4%)	224 (2.1%)	0.32 (-0.18, 0.77)	87 (2.0%)	94 (1.8%)	0.24 (-0.32, 0.78)
	50-59	196 (2.3%)	259 (1.7%)	0.60 (0.23, 0.98)	110 (1.7%)	90 (1.1%)	0.64 (0.25, 1.02)
	60-69	60 (1.2%)	111 (1.0%)	0.17 (-0.16, 0.50)	57 (1.3%)	53 (0.7%)	0.56 (0.24, 0.92)
	70+	22 (0.8%)	19 (0.4%)	0.39 (0.06, 0.77)	31 (1.0%)	14 (0.2%)	0.72 (0.39, 1.08)

(page 4 of 7)

			Female (n = 93 494	4)		Male (n = 59 386)	
Symptom	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Headache	15-19	121 (8.0%)	120 (5.5%)	2.59 (0.99, 4.33)	34 (4.1%)	51 (5.0%)	-0.99 (-2.96, 0.86)
	20-29	460 (7.8%)	329 (5.2%)	2.68 (1.80, 3.63)	163 (5.2%)	129 (4.8%)	0.44 (-0.70, 1.59)
	30-39	504 (10.2%)	326 (5.0%)	5.26 (4.28, 6.17)	206 (6.8%)	135 (4.1%)	2.77 (1.53, 3.92)
	40-49	599 (8.5%)	421 (3.9%)	4.59 (3.86, 5.33)	265 (6.1%)	200 (3.8%)	2.37 (1.49, 3.28)
	50-59	657 (7.7%)	482 (3.1%)	4.52 (3.90, 5.16)	244 (3.8%)	219 (2.6%)	1.21 (0.62, 1.82)
	60-69	241 (4.8%)	223 (2.0%)	2.71 (2.07, 3.39)	146 (3.3%)	138 (1.8%)	1.48 (0.91, 2.10)
	70+	59 (2.1%)	58 (1.1%)	0.99 (0.40, 1.59)	41 (1.4%)	37 (0.7%)	0.71 (0.24, 1.19)
Hot flushes/sweat	15-19	66 (4.4%)	71 (3.3%)	1.24 (-0.13, 2.66)	17 (2.0%)	21 (2.1%)	-0.02 (-1.41, 1.52)
	20-29	253 (4.3%)	229 (3.6%)	0.75 (0.01, 1.47)	63 (2.0%)	49 (1.8%)	0.24 (-0.53, 1.01)
	30-39	227 (4.6%)	188 (2.9%)	1.83 (1.15, 2.57)	90 (3.0%)	71 (2.2%)	0.89 (0.06, 1.73)
	40-49	358 (5.1%)	261 (2.4%)	2.70 (2.13, 3.29)	118 (2.7%)	98 (1.8%)	0.90 (0.28, 1.53)
	50-59	386 (4.5%)	228 (1.5%)	2.98 (2.53, 3.47)	161 (2.5%)	98 (1.2%)	1.33 (0.89, 1.75)
	60-69	152 (3.0%)	120 (1.1%)	1.83 (1.34, 2.34)	74 (1.7%)	67 (0.9%)	0.75 (0.36, 1.14)
	70+	48 (1.7%)	29 (0.5%)	1.08 (0.63, 1.59)	34 (1.1%)	20 (0.4%)	0.73 (0.34, 1.13)
Dysosmia	15-19	207 (13.7%)	52 (2.4%)	11.77 (9.80, 13.72)	83 (9.9%)	18 (1.8%)	8.46 (6.08, 10.72)
	20-29	854 (14.5%)	77 (1.2%)	13.60 (12.61, 14.61)	401 (12.8%)	17 (0.6%)	12.57 (11.3, 13.82)
	30-39	743 (15.0%)	64 (1.0%)	14.13 (13.07, 15.19)	370 (12.3%)	23 (0.7%)	11.84 (10.65, 13.13)
	40-49	1057 (15.0%)	106 (1.0%)	14.01 (13.14, 14.90)	484 (11.2%)	38 (0.7%)	10.55 (9.62, 11.62)
	50-59	1068 (12.5%)	92 (0.6%)	11.79 (11.07, 12.49)	531 (8.3%)	40 (0.5%)	7.80 (7.11, 8.47)
	60-69	407 (8.0%)	39 (0.3%)	7.54 (6.78, 8.31)	269 (6.0%)	19 (0.2%)	5.69 (4.95, 6.38)
	70+	109 (3.9%)	9 (0.2%)	3.66 (2.99, 4.42)	91 (3.1%)	10 (0.2%)	2.85 (2.27, 3.49)

(page 5 of 7)

			Female (n = 93 494	4)		Male (n = 59 386)	
Symptom	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Dysgeusia	15-19	155 (10.3%)	27 (1.2%)	9.56 (7.87, 11.23)	59 (7.0%)	5 (0.5%)	6.97 (5.25, 8.92)
	20-29	635 (10.8%)	64 (1.0%)	10.19 (9.30, 11.09)	303 (9.7%)	18 (0.7%)	9.54 (8.38, 10.74)
	30-39	591 (11.9%)	63 (1.0%)	11.21 (10.26, 12.31)	273 (9.0%)	19 (0.6%)	8.85 (7.68, 10.01)
	40-49	858 (12.2%)	107 (1.0%)	11.26 (10.51, 11.97)	378 (8.7%)	34 (0.6%)	8.25 (7.39, 9.16)
	50-59	917 (10.7%)	88 (0.6%)	10.05 (9.42, 10.75)	428 (6.7%)	37 (0.4%)	6.24 (5.65, 6.88)
	60-69	348 (6.9%)	46 (0.4%)	6.26 (5.57, 6.96)	221 (5.0%)	20 (0.3%)	4.56 (3.93, 5.22)
	70+	114 (4.0%)	15 (0.3%)	3.60 (2.90, 4.32)	85 (2.9%)	8 (0.1%)	2.58 (2.03, 3.20)
Muscle/joint pain	15-19	64 (4.2%)	74 (3.4%)	0.89 (-0.42, 2.23)	15 (1.8%)	14 (1.4%)	0.46 (-0.71, 1.64)
	20-29	293 (5.0%)	218 (3.5%)	1.61 (0.86, 2.35)	96 (3.1%)	68 (2.5%)	0.59 (-0.27, 1.53)
	30-39	363 (7.3%)	238 (3.6%)	3.79 (2.91, 4.61)	150 (5.0%)	99 (3.0%)	2.02 (0.97, 3.08)
	40-49	525 (7.5%)	291 (2.7%)	4.76 (4.08, 5.39)	217 (5.0%)	115 (2.2%)	2.88 (2.14, 3.64)
	50-59	606 (7.1%)	266 (1.7%)	5.30 (4.72, 5.92)	331 (5.2%)	123 (1.5%)	3.68 (3.11, 4.29)
	60-69	241 (4.8%)	113 (1.0%)	3.66 (3.04, 4.29)	180 (4.0%)	87 (1.1%)	2.84 (2.27, 3.44)
	70+	63 (2.2%)	29 (0.5%)	1.66 (1.08, 2.28)	73 (2.5%)	37 (0.7%)	1.74 (1.22, 2.31)
Nausea	15-19	57 (3.8%)	70 (3.2%)	0.66 (-0.75, 2.09)	10 (1.2%)	19 (1.9%)	-0.80 (-2.11, 0.45)
	20-29	223 (3.8%)	216 (3.4%)	0.44 (-0.31, 1.23)	45 (1.4%)	33 (1.2%)	0.28 (-0.43, 0.99)
	30-39	163 (3.3%)	214 (3.3%)	0.08 (-0.69, 0.85)	52 (1.7%)	58 (1.8%)	-0.03 (-0.76, 0.68)
	40-49	178 (2.5%)	197 (1.8%)	0.72 (0.25, 1.19)	42 (1.0%)	49 (0.9%)	0.04 (-0.35, 0.49)
	50-59	203 (2.4%)	214 (1.4%)	0.96 (0.61, 1.35)	59 (0.9%)	44 (0.5%)	0.39 (0.10, 0.65)
	60-69	72 (1.4%)	110 (1.0%)	0.39 (0.03, 0.77)	30 (0.7%)	29 (0.4%)	0.27 (0.02, 0.51)
	70+	31 (1.1%)	25 (0.5%)	0.55 (0.18, 0.94)	14 (0.5%)	16 (0.3%)	0.15 (-0.08, 0.38)

(page 6 of 7)

		Female (n = 93 494)			Male (n = 59 386)	
Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
15-19	27 (1.8%)	54 (2.5%)	-0.78 (-1.78, 0.22)	6 (0.7%)	19 (1.9%)	-1.26 (-2.38, -0.16)
20-29	94 (1.6%)	92 (1.5%)	0.15 (-0.32, 0.63)	35 (1.1%)	20 (0.7%)	0.42 (-0.12, 0.94)
30-39	88 (1.8%)	82 (1.2%)	0.57 (0.08, 1.10)	40 (1.3%)	27 (0.8%)	0.55 (0.02, 1.09)
40-49	137 (1.9%)	113 (1.0%)	0.92 (0.54, 1.32)	39 (0.9%)	31 (0.6%)	0.31 (-0.05, 0.67)
50-59	155 (1.8%)	126 (0.8%)	0.98 (0.65, 1.28)	63 (1.0%)	57 (0.7%)	0.29 (0.00, 0.58)
60-69	59 (1.2%)	53 (0.5%)	0.65 (0.32, 0.95)	38 (0.9%)	41 (0.5%)	0.30 (0.01, 0.59)
70+	20 (0.7%)	15 (0.3%)	0.38 (0.09, 0.70)	21 (0.7%)	18 (0.3%)	0.33 (0.05, 0.66)
15-19	115 (7.6%)	71 (3.3%)	4.89 (3.24, 6.62)	32 (3.8%)	15 (1.5%)	2.63 (1.10, 4.28)
20-29	297 (5.0%)	200 (3.2%)	2.08 (1.30, 2.81)	89 (2.8%)	37 (1.4%)	1.68 (0.91, 2.43)
30-39	215 (4.3%)	173 (2.6%)	1.86 (1.11, 2.61)	73 (2.4%)	43 (1.3%)	1.24 (0.51, 2.01)
40-49	222 (3.2%)	181 (1.7%)	1.53 (1.03, 2.04)	86 (2.0%)	53 (1.0%)	1.03 (0.52, 1.56)
50-59	239 (2.8%)	164 (1.1%)	1.72 (1.35, 2.11)	116 (1.8%)	53 (0.6%)	1.17 (0.79, 1.52)
60-69	101 (2.0%)	90 (0.8%)	1.11 (0.73, 1.54)	62 (1.4%)	35 (0.4%)	0.86 (0.54, 1.21)
70+	70 (2.5%)	33 (0.6%)	1.63 (1.10, 2.17)	55 (1.8%)	28 (0.5%)	1.14 (0.73, 1.64)
15-19	50 (3.3%)	39 (1.8%)	1.75 (0.54, 2.95)	17 (2.0%)	5 (0.5%)	1.76 (0.61, 3.03)
20-29	195 (3.3%)	84 (1.3%)	2.25 (1.64, 2.85)	84 (2.7%)	21 (0.8%)	2.17 (1.47, 2.92)
30-39	294 (5.9%)	112 (1.7%)	4.63 (3.81, 5.41)	140 (4.6%)	48 (1.5%)	3.43 (2.58, 4.36)
40-49	488 (6.9%)	147 (1.4%)	5.79 (5.16, 6.43)	237 (5.5%)	79 (1.5%)	4.03 (3.27, 4.80)
50-59	673 (7.9%)	195 (1.3%)	6.63 (6.03, 7.25)	421 (6.6%)	86 (1.0%)	5.34 (4.67, 5.95)
60-69	315 (6.2%)	75 (0.7%)	5.32 (4.68, 6.02)	234 (5.2%)	56 (0.7%)	4.09 (3.51, 4.68)
70+	104 (3.7%)	36 (0.7%)	2.71 (2.03, 3.38)	129 (4.3%)	41 (0.7%)	3.11 (2.42, 3.83)
	15-19 $20-29$ $30-39$ $40-49$ $50-59$ $60-69$ $70+$ $15-19$ $20-29$ $30-39$ $40-49$ $50-59$ $60-69$ $70+$ $15-19$ $20-29$ $30-39$ $40-49$ $50-59$ $60-69$ $70+$	15 19 27 (1.8%)20-2994 (1.6%)30-3988 (1.8%)40-49137 (1.9%)50-59155 (1.8%)60-6959 (1.2%)70+20 (0.7%)15-19115 (7.6%)20-29297 (5.0%)30-39215 (4.3%)40-49222 (3.2%)50-59239 (2.8%)60-69101 (2.0%)70+70 (2.5%)15-1950 (3.3%)20-29195 (3.3%)30-39294 (5.9%)40-49488 (6.9%)50-59673 (7.9%)60-69315 (6.2%)	Age (years)Positive (n, %)Negative (n, %) $15-19$ $27 (1.8\%)$ $54 (2.5\%)$ $20-29$ $94 (1.6\%)$ $92 (1.5\%)$ $30-39$ $88 (1.8\%)$ $82 (1.2\%)$ $40-49$ $137 (1.9\%)$ $113 (1.0\%)$ $50-59$ $155 (1.8\%)$ $126 (0.8\%)$ $60-69$ $59 (1.2\%)$ $53 (0.5\%)$ $70+$ $20 (0.7\%)$ $15 (0.3\%)$ $15-19$ $115 (7.6\%)$ $71 (3.3\%)$ $20-29$ $297 (5.0\%)$ $200 (3.2\%)$ $30-39$ $215 (4.3\%)$ $173 (2.6\%)$ $40-49$ $222 (3.2\%)$ $181 (1.7\%)$ $50-59$ $239 (2.8\%)$ $164 (1.1\%)$ $60-69$ $101 (2.0\%)$ $90 (0.8\%)$ $70+$ $70 (2.5\%)$ $33 (0.6\%)$ $15-19$ $50 (3.3\%)$ $39 (1.8\%)$ $20-29$ $195 (3.3\%)$ $84 (1.3\%)$ $30-39$ $294 (5.9\%)$ $112 (1.7\%)$ $40-49$ $488 (6.9\%)$ $147 (1.4\%)$ $50-59$ $673 (7.9\%)$ $195 (1.3\%)$ $60-69$ $315 (6.2\%)$ $75 (0.7\%)$	Age (years)Positive (n, %)Negative (n, %)RD (95% CI) $15 \cdot 19$ 27 (1.8%)54 (2.5%) -0.78 (-1.78, 0.22) $20 \cdot 29$ 94 (1.6%)92 (1.5%)0.15 (-0.32, 0.63) $30 \cdot 39$ 88 (1.8%)82 (1.2%)0.57 (0.08, 1.10) $40 \cdot 49$ 137 (1.9%)113 (1.0%)0.92 (0.54, 1.32) $50 \cdot 59$ 155 (1.8%)126 (0.8%)0.98 (0.65, 1.28) $60 \cdot 69$ 59 (1.2%)53 (0.5%)0.65 (0.32, 0.95) $70 +$ 20 (0.7%)15 (0.3%)0.38 (0.09, 0.70)15 - 19115 (7.6%)71 (3.3%)4.89 (3.24, 6.62) $20 \cdot 29$ 297 (5.0%)200 (3.2%)2.08 (1.30, 2.81) $30 \cdot 39$ 215 (4.3%)173 (2.6%)1.86 (1.11, 2.61) $40 \cdot 49$ 222 (3.2%)181 (1.7%)1.53 (1.03, 2.04) $50 \cdot 59$ 239 (2.8%)164 (1.1%)1.72 (1.35, 2.11) $60 \cdot 69$ 101 (2.0%)90 (0.8%)1.11 (0.73, 1.54) $70 \cdot$ 70 (2.5%)33 (0.6%)1.63 (1.10, 2.17)15 - 1950 (3.3%)39 (1.8%)1.75 (0.54, 2.95)20 - 29195 (3.3%)84 (1.3%)2.25 (1.64, 2.85)30 - 39294 (5.9%)112 (1.7%)4.63 (3.81, 5.41) $40 \cdot 49$ 488 (6.9%)147 (1.4%)5.79 (5.16, 6.43) $50 \cdot 59$ 673 (7.9%)195 (1.3%)6.63 (6.03, 7.25) $60 \cdot 69$ 315 (6.2%)75 (0.7%)5.32 (4.68, 6.02)	Age (years)Positive (n, %)Negative (n, %)RD (95% CI)Positive (n, %)15-1927 (1.8%)54 (2.5%) -0.78 (-1.78, 0.22)6 (0.7%)20-2994 (1.6%)92 (1.5%) 0.15 (-0.32 , 0.63)35 (1.1%)30-3988 (1.8%)82 (1.2%) 0.57 (0.08, 1.10)40 (1.3%)40-49137 (1.9%)113 (1.0%) 0.92 (0.54, 1.32)39 (0.9%)50-59155 (1.8%)126 (0.8%) 0.98 (0.65, 1.28)63 (1.0%)60-6959 (1.2%)53 (0.5%) 0.65 (0.32, 0.95)38 (0.9%)70+20 (0.7%)15 (0.3%) 0.38 (0.09, 0.70)21 (0.7%)15-19115 (7.6%)71 (3.3%)4.89 (3.24, 6.62)32 (3.8%)20-29297 (5.0%)200 (3.2%)2.08 (1.30, 2.81)89 (2.8%)30-39215 (4.3%)173 (2.6%)1.86 (1.11, 2.61)73 (2.4%)40-49222 (3.2%)181 (1.7%)1.53 (1.03, 2.04)86 (2.0%)50-59239 (2.8%)164 (1.1%)1.72 (1.35, 2.11)116 (1.8%)60-69101 (2.0%)90 (0.8%)1.11 (0.73, 1.54)62 (1.4%)70+70 (2.5%)39 (1.8%)1.75 (0.54, 2.95)17 (2.0%)20-29195 (3.3%)84 (1.3%)2.25 (1.64, 2.85)84 (2.7%)30-39294 (5.9%)112 (1.7%)4.63 (3.81, 5.41)140 (4.6%)40-49488 (6.9%)147 (1.4%)5.79 (5.16, 6.43)237 (5.5%)50-59673 (7.9%)195 (1.3%)6.63 (6.03, 7.25)421 (6.6%)60-69 <td< td=""><td>Age (years)Positive (n, %)Negative (n, %)RD (95% CI)Positive (n, %)Negative (n, %)$15-19$27 (1.8%)54 (2.5%)-0.78 (-1.78, 0.22)6 (0.7%)19 (1.9%)$20-29$94 (1.6%)92 (1.5%)0.15 (-0.32, 0.63)35 (1.1%)20 (0.7%)$30-39$88 (1.8%)82 (1.2%)0.57 (0.08, 1.10)40 (1.3%)27 (0.8%)$40-49$137 (1.9%)113 (1.0%)0.92 (0.54, 1.32)39 (0.9%)31 (0.6%)$50-59$155 (1.8%)126 (0.8%)0.98 (0.65, 1.28)63 (1.0%)57 (0.7%)$60-69$59 (1.2%)53 (0.5%)0.65 (0.32, 0.95)38 (0.9%)41 (0.5%)$70+$20 (0.7%)15 (0.3%)0.38 (0.09, 0.70)21 (0.7%)18 (0.3%)$15-19$115 (7.6%)71 (3.3%)4.89 (3.24, 6.62)32 (3.8%)15 (1.5%)$20-29$297 (5.0%)200 (3.2%)2.08 (1.30, 2.81)89 (2.8%)37 (1.4%)$30-39$215 (4.3%)173 (2.6%)1.86 (1.11, 2.61)73 (2.4%)43 (1.3%)$40-49$222 (3.2%)181 (1.7%)1.53 (1.03, 2.04)86 (2.0%)53 (1.0%)$50-59$239 (2.8%)164 (1.1%)1.72 (1.35, 2.11)116 (1.8%)53 (0.6%)$60-69$101 (2.0%)90 (0.8%)1.11 (0.73, 1.54)62 (1.4%)35 (0.4%)$70+$70 (2.5%)33 (0.6%)1.63 (1.10, 2.17)55 (1.8%)28 (0.5%)$15-19$50 (3.3%)39 (1.8%)1.75 (0.54, 2.95)17 (2.0%)5 (0.5%)$20-29$195 (3.3%</td></td<>	Age (years)Positive (n, %)Negative (n, %)RD (95% CI)Positive (n, %)Negative (n, %) $15-19$ 27 (1.8%)54 (2.5%) -0.78 (-1.78, 0.22)6 (0.7%)19 (1.9%) $20-29$ 94 (1.6%)92 (1.5%)0.15 (-0.32, 0.63)35 (1.1%)20 (0.7%) $30-39$ 88 (1.8%)82 (1.2%)0.57 (0.08, 1.10)40 (1.3%)27 (0.8%) $40-49$ 137 (1.9%)113 (1.0%)0.92 (0.54, 1.32)39 (0.9%)31 (0.6%) $50-59$ 155 (1.8%)126 (0.8%)0.98 (0.65, 1.28)63 (1.0%)57 (0.7%) $60-69$ 59 (1.2%)53 (0.5%)0.65 (0.32, 0.95)38 (0.9%)41 (0.5%) $70+$ 20 (0.7%)15 (0.3%)0.38 (0.09, 0.70)21 (0.7%)18 (0.3%) $15-19$ 115 (7.6%)71 (3.3%)4.89 (3.24, 6.62)32 (3.8%)15 (1.5%) $20-29$ 297 (5.0%)200 (3.2%)2.08 (1.30, 2.81)89 (2.8%)37 (1.4%) $30-39$ 215 (4.3%)173 (2.6%)1.86 (1.11, 2.61)73 (2.4%)43 (1.3%) $40-49$ 222 (3.2%)181 (1.7%)1.53 (1.03, 2.04)86 (2.0%)53 (1.0%) $50-59$ 239 (2.8%)164 (1.1%)1.72 (1.35, 2.11)116 (1.8%)53 (0.6%) $60-69$ 101 (2.0%)90 (0.8%)1.11 (0.73, 1.54)62 (1.4%)35 (0.4%) $70+$ 70 (2.5%)33 (0.6%)1.63 (1.10, 2.17)55 (1.8%)28 (0.5%) $15-19$ 50 (3.3%)39 (1.8%)1.75 (0.54, 2.95)17 (2.0%)5 (0.5%) $20-29$ 195 (3.3%

(page 7 of 7)

			Female (n = 93 494))		Male (n = 59 386)	
Symptom	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Runny nose	15-19	122 (8.1%)	206 (9.5%)	-1.52 (-3.39, 0.43)	41 (4.9%)	87 (8.5%)	-3.82 (-6.18, -1.53)
	20-29	368 (6.3%)	478 (7.6%)	-1.39 (-2.29, -0.45)	145 (4.6%)	148 (5.5%)	-0.89 (-2.08, 0.36)
	30-39	250 (5.0%)	389 (5.9%)	-0.89 (-1.73, -0.02)	122 (4.0%)	140 (4.3%)	-0.22 (-1.21, 0.77)
	40-49	285 (4.0%)	504 (4.7%)	-0.66 (-1.23, -0.06)	157 (3.6%)	217 (4.1%)	-0.47 (-1.20, 0.32)
	50-59	348 (4.1%)	536 (3.5%)	0.58 (0.04, 1.06)	175 (2.7%)	213 (2.5%)	0.19 (-0.30, 0.75)
	60-69	157 (3.1%)	249 (2.2%)	0.83 (0.37, 1.40)	107 (2.4%)	151 (1.9%)	0.44 (-0.11, 0.97)
	70+	51 (1.8%)	71 (1.3%)	0.44 (-0.14, 1.03)	48 (1.6%)	85 (1.5%)	0.09 (-0.41, 0.65)
Sleeping legs/arms	15-19	54 (3.6%)	41 (1.9%)	1.91 (0.68, 3.14)	12 (1.4%)	10 (1.0%)	0.51 (-0.61, 1.60)
	20-29	193 (3.3%)	123 (2.0%)	1.49 (0.88, 2.12)	71 (2.3%)	38 (1.4%)	0.99 (0.25, 1.82)
	30-39	301 (6.1%)	147 (2.2%)	4.11 (3.34, 4.90)	122 (4.0%)	45 (1.4%)	2.90 (2.05, 3.82)
	40-49	475 (6.7%)	201 (1.9%)	4.99 (4.39, 5.66)	169 (3.9%)	72 (1.4%)	2.60 (1.91, 3.33)
	50-59	557 (6.5%)	228 (1.5%)	4.98 (4.37, 5.54)	297 (4.6%)	81 (1.0%)	3.59 (3.05, 4.14)
	60-69	255 (5.0%)	109 (1.0%)	3.85 (3.26, 4.41)	167 (3.7%)	68 (0.9%)	2.65 (2.14, 3.22)
	70+	81 (2.9%)	35 (0.7%)	2.02 (1.43, 2.65)	87 (2.9%)	38 (0.7%)	2.01 (1.40, 2.58)
Sore throat	15-19	128 (8.5%)	223 (10.3%)	-1.96 (-3.95, -0.02)	41 (4.9%)	97 (9.5%)	-4.93 (-7.47, -2.54)
	20-29	384 (6.5%)	518 (8.3%)	-1.77 (-2.77, -0.78)	146 (4.7%)	156 (5.8%)	-1.16 (-2.26, 0.12)
	30-39	242 (4.9%)	387 (5.9%)	-1.00 (-1.78, -0.17)	112 (3.7%)	145 (4.4%)	-0.72 (-1.70, 0.22)
	40-49	324 (4.6%)	613 (5.7%)	-1.10 (-1.75, -0.43)	135 (3.1%)	195 (3.7%)	-0.57 (-1.25, 0.17)
	50-59	341 (4.0%)	608 (3.9%)	0.04 (-0.46, 0.56)	146 (2.3%)	192 (2.3%)	-0.01 (-0.51, 0.45)
	60-69	138 (2.7%)	296 (2.7%)	0.05 (-0.46, 0.57)	65 (1.5%)	130 (1.7%)	-0.20 (-0.63, 0.22)
	70+	43 (1.5%)	80 (1.5%)	0.00 (-0.48, 0.55)	37 (1.2%)	50 (0.9%)	0.33 (-0.13, 0.79)

(page 1 of 2)

			Female (n = 93 494	emale (n = 93 494) Male (n = 59 386)			
Medical diagnosis	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Difficulties concentrating	15-19	407 (33.0%)	161 (9.6%)	25.16 (22.03, 28.21)	123 (17.1%)	43 (5.1%)	13.32 (10.04, 16.98)
U	20-29	1712 (33.8%)	279 (5.4%)	30.19 (28.87, 31.74)	628 (22.5%)	102 (4.5%)	19.83 (17.91, 21.70)
	30-39	1711 (37.9%)	316 (5.5%)	33.70 (32.16, 35.29)	754 (27.0%)	100 (3.4%)	25.20 (23.36, 27.03)
	40-49	2562 (39.5%)	442 (4.7%)	35.55 (34.32, 36.79)	1136 (27.8%)	156 (3.2%)	25.43 (23.97, 26.91)
	50-59	2966 (37.6%)	531 (3.8%)	33.68 (32.49, 34.80)	1638 (26.8%)	206 (2.6%)	24.24 (23.15, 25.40)
	60-69	1324 (27.6%)	197 (1.9%)	24.85 (23.54, 26.11)	926 (21.6%)	130 (1.7%)	19.02 (17.79, 20.22)
	70+	428 (15.7%)	61 (1.2%)	13.58 (12.20, 14.98)	405 (14.2%)	88 (1.6%)	11.46 (10.18, 12.67)
Memory issues	15-19	350 (26.0%)	103 (5.5%)	22.46 (19.68, 25.17)	105 (13.7%)	34 (3.6%)	11.14 (7.96, 14.23)
	20-29	1502 (28.1%)	286 (5.3%)	24.58 (23.12, 25.99)	496 (17.0%)	91 (3.8%)	14.75 (12.99, 16.45)
	30-39	1616 (36.1%)	331 (5.9%)	31.76 (30.22, 33.35)	592 (21.0%)	93 (3.1%)	19.24 (17.51, 21.05)
	40-49	2532 (40.0%)	481 (5.2%)	35.72 (34.34, 37.03)	1072 (26.3%)	175 (3.6%)	23.54 (22.17, 25.09)
	50-59	3075 (39.4%)	583 (4.3%)	35.20 (34.08, 36.46)	1582 (26.0%)	245 (3.1%)	22.84 (21.70, 24.04)
	60-69	1376 (29.0%)	260 (2.5%)	25.65 (24.41, 26.87)	944 (22.5%)	160 (2.2%)	19.27 (18.09, 20.50)
	70+	450 (17.0%)	82 (1.7%)	14.18 (12.84, 15.56)	457 (16.6%)	133 (2.6%)	12.62 (11.32, 14.00)
Mental exhaustion	15-19	537 (46.8%)	280 (18.9%)	29.19 (25.48, 33.05)	176 (24.3%)	82 (9.8%)	15.76 (11.94, 19.56)
	20-29	2228 (46.0%)	634 (14.2%)	33.14 (31.27, 34.90)	796 (28.8%)	251 (11.7%)	18.53 (16.27, 20.63)
	30-39	2047 (47.6%)	638 (12.5%)	36.17 (34.33, 38.04)	941 (34.7%)	227 (8.4%)	27.70 (25.61, 29.80)
	40-49	3049 (48.9%)	920 (10.4%)	39.11 (37.73, 40.48)	1421 (35.7%)	346 (7.5%)	28.97 (27.13, 30.68)
	50-59	3652 (47.0%)	1069 (8.1%)	38.96 (37.76, 40.15)	2089 (34.3%)	457 (6.0%)	28.44 (27.12, 29.92)
	60-69	1737 (36.3%)	474 (4.7%)	30.96 (29.54, 32.37)	1145 (26.8%)	273 (3.7%)	22.30 (21.01, 23.62)
	70+	544 (20.0%)	98 (2.0%)	17.36 (15.78, 18.81)	448 (15.6%)	128 (2.4%)	12.27 (10.92, 13.54)

(page 2 of 2)

			Female (n = 93 494	4)		Male (n = 59 386)	
Medical diagnosis	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Physical exhaustion	15-19	608 (46.4%)	213 (12.2%)	36.32 (33.11, 39.50)	179 (23.2%)	58 (6.5%)	18.47 (14.70, 22.24)
	20-29	2466 (47.3%)	547 (10.6%)	38.42 (36.69, 40.07)	895 (31.0%)	195 (8.4%)	24.67 (22.43, 26.79)
	30-39	2290 (51.4%)	593 (10.9%)	41.81 (40.00, 43.65)	1121 (40.3%)	205 (7.1%)	34.97 (32.87, 37.18)
	40-49	3544 (55.3%)	875 (9.5%)	46.54 (45.16, 47.81)	1798 (44.4%)	330 (6.9%)	38.63 (36.89, 40.32)
	50-59	4302 (54.7%)	1109 (8.2%)	46.74 (45.52, 48.02)	2639 (43.5%)	446 (5.8%)	37.94 (36.57, 39.36)
	60-69	2262 (47.6%)	580 (5.8%)	41.15 (39.79, 42.54)	1663 (39.7%)	335 (4.7%)	34.05 (32.45, 35.43)
	70+	887 (34.1%)	176 (3.7%)	29.34 (27.48, 31.20)	838 (30.5%)	217 (4.2%)	24.64 (22.85, 26.40)
Sleep problems	15-19	292 (23.9%)	193 (11.3%)	13.45 (10.61, 16.43)	112 (15.6%)	60 (7.1%)	9.14 (5.73, 12.53)
	20-29	1054 (21.6%)	425 (8.7%)	13.72 (12.13, 15.22)	431 (15.9%)	168 (7.7%)	9.02 (7.07, 10.90)
	30-39	988 (23.2%)	458 (8.6%)	15.30 (13.77, 16.83)	466 (17.6%)	157 (5.7%)	12.72 (10.91, 14.43)
	40-49	1600 (27.1%)	740 (8.4%)	19.03 (17.79, 20.41)	774 (20.4%)	292 (6.4%)	14.31 (12.81, 15.78)
	50-59	2278 (33.4%)	1006 (8.3%)	23.98 (23.81, 26.14)	1214 (21.3%)	380 (5.2%)	16.02 (14.82, 17.20)
	60-69	1071 (26.0%)	483 (5.4%)	19.96 (18.57, 21.30)	780 (19.4%)	257 (3.7%)	14.92 (13.73, 16.13)
	70+	443 (19.1%)	157 (3.6%)	14.52 (13.14, 16.11)	347 (12.8%)	160 (3.1%)	8.82 (7.57, 10.03)

Table S6: Risk differences of self-reported diagnoses after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group

(page 1 of 2)

			Female (n = 93 494)			Male (n = 59 386)	
Medical diagnosis	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Depression	15-19	87 (6.2%)	99 (5.1%)	1.16 (-0.47, 2.78)	29 (3.6%)	26 (2.7%)	0.94 (-0.77, 2.70)
	20-29	244 (4.8%)	177 (3.3%)	1.62 (0.81, 2.50)	105 (3.6%)	82 (3.4%)	0.29 (-0.81, 1.36)
	30-39	188 (4.5%)	118 (2.2%)	2.51 (1.73, 3.32)	91 (3.3%)	61 (2.1%)	1.33 (0.38, 2.26)
	40-49	194 (3.2%)	182 (2.0%)	1.26 (0.69, 1.82)	119 (3.0%)	92 (1.9%)	1.10 (0.37, 1.86)
	50-59	227 (3.0%)	284 (2.1%)	0.87 (0.43, 1.30)	174 (2.9%)	180 (2.3%)	0.57 (0.02, 1.14)
	60-69	116 (2.6%)	200 (2.0%)	0.48 (-0.05, 0.97)	119 (2.9%)	158 (2.2%)	0.62 (0.11, 1.17)
	70+	101 (3.9%)	112 (2.3%)	1.38 (0.66, 2.11)	89 (3.2%)	99 (1.8%)	1.08 (0.46, 1.68)
Anxiety	15-19	77 (5.9%)	103 (5.6%)	0.26 (-1.48, 1.97)	24 (3.0%)	18 (1.9%)	1.17 (-0.31, 2.79)
	20-29	310 (6.2%)	174 (3.3%)	3.10 (2.21, 3.98)	114 (3.9%)	70 (2.8%)	1.16 (0.16, 2.23)
	30-39	218 (5.0%)	126 (2.2%)	2.94 (2.08, 3.75)	84 (3.0%)	48 (1.6%)	1.48 (0.59, 2.25)
	40-49	211 (3.3%)	178 (1.8%)	1.53 (1.01, 2.06)	104 (2.5%)	79 (1.6%)	0.98 (0.40, 1.54)
	50-59	237 (3.0%)	274 (1.9%)	1.03 (0.61, 1.46)	150 (2.4%)	154 (1.9%)	0.51 (0.04, 0.96)
	60-69	109 (2.3%)	213 (2.0%)	0.19 (-0.28, 0.67)	99 (2.3%)	158 (2.1%)	0.17 (-0.35, 0.64)
	70+	88 (3.2%)	104 (2.1%)	1.04 (0.38, 1.69)	75 (2.6%)	84 (1.5%)	0.90 (0.32, 1.50)
PTSD	15-19	19 (1.3%)	19 (0.9%)	0.39 (-0.29, 1.16)	6 (0.7%)	7 (0.7%)	0.03 (-0.76, 0.79)
	20-29	52 (0.9%)	38 (0.6%)	0.30 (-0.05, 0.60)	28 (0.9%)	23 (0.9%)	0.05 (-0.48, 0.54)
	30-39	72 (1.5%)	40 (0.6%)	0.91 (0.51, 1.31)	36 (1.2%)	22 (0.7%)	0.55 (0.05, 1.05)
	40-49	95 (1.4%)	103 (1.0%)	0.42 (0.07, 0.77)	57 (1.3%)	63 (1.2%)	0.13 (-0.33, 0.58)
	50-59	116 (1.4%)	200 (1.3%)	0.04 (-0.25, 0.34)	94 (1.5%)	127 (1.5%)	-0.04 (-0.43, 0.38)
	60-69	66 (1.3%)	165 (1.5%)	-0.19 (-0.58, 0.18)	67 (1.5%)	143 (1.9%)	-0.31 (-0.75, 0.13)
	70+	31 (1.1%)	78 (1.5%)	-0.34 (-0.78, 0.09)	30 (1.0%)	72 (1.3%)	-0.25 (-0.62, 0.18)

(page 2 of 2)

		Female (n = 93 494)			Male (n = 59 386)			
Medical diagnosis	Age (years)	Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)	
Chronic fatigue syndrome	15-19	58 (3.9%)	27 (1.3%)	2.89 (1.75, 4.12)	16 (1.9%)	5 (0.5%)	1.61 (0.56, 2.90)	
5	20-29	192 (3.3%)	40 (0.6%)	2.98 (2.38, 3.51)	80 (2.6%)	26 (1.0%)	1.86 (1.13, 2.58)	
	30-39	209 (4.3%)	39 (0.6%)	4.00 (3.39, 4.66)	101 (3.4%)	27 (0.8%)	2.80 (2.03, 3.57)	
	40-49	268 (3.9%)	120 (1.1%)	2.86 (2.35, 3.43)	153 (3.6%)	67 (1.3%)	2.39 (1.71, 3.03)	
	50-59	330 (3.9%)	219 (1.4%)	2.46 (2.03, 2.93)	270 (4.3%)	152 (1.8%)	2.42 (1.83, 3.04)	
	60-69	198 (4.0%)	208 (1.9%)	1.94 (1.38, 2.54)	203 (4.6%)	174 (2.3%)	2.17 (1.52, 2.77)	
	70+	169 (6.1%)	117 (2.3%)	3.25 (2.40, 4.12)	154 (5.3%)	108 (2.0%)	2.81 (2.05, 3.65)	
Fibromyalgia	15-19	15 (1.0%)	6 (0.3%)	0.75 (0.22, 1.36)	6 (0.7%)	5 (0.5%)	0.24 (-0.54, 0.99)	
	20-29	36 (0.6%)	20 (0.3%)	0.32 (0.06, 0.56)	20 (0.6%)	20 (0.7%)	-0.10 (-0.57, 0.36)	
	30-39	44 (0.9%)	30 (0.5%)	0.46 (0.15, 0.80)	27 (0.9%)	21 (0.6%)	0.27 (-0.20, 0.71)	
	40-49	77 (1.1%)	92 (0.9%)	0.25 (-0.06, 0.55)	49 (1.1%)	52 (1.0%)	0.15 (-0.25, 0.55)	
	50-59	83 (1.0%)	171 (1.1%)	-0.15 (-0.43, 0.12)	85 (1.3%)	114 (1.4%)	-0.02 (-0.41, 0.37)	
	60-69	52 (1.0%)	165 (1.5%)	-0.47 (-0.84, -0.11)	60 (1.4%)	138 (1.8%)	-0.41 (-0.81, 0.05)	
	70+	40 (1.4%)	80 (1.5%)	-0.10 (-0.62, 0.41)	26 (0.9%)	72 (1.3%)	-0.38 (-0.78, 0.02)	

Figure S1: Risk differences of symptoms around the test date, comparing SARS-CoV-2 test-positive and test-negative participants.

Symptom	Positive (n,%)	Negative (n,%)		1				Risk Difference (95% CI)
Dysgeusia	22,419 (36.8%)	237 (5.3%)		1			-	34.49 (33.74, 35.28)
Dysosmia	21,884 (35.9%)	247 (5.5%)		1				33.87 (33.06, 34.73)
Fever	33,577 (55.0%)	1,453 (32.5%)		1		-•-		23.90 (22.35, 25.28)
Chills	22,800 (37.4%)	810 (18.1%)		1		-•-		21.86 (20.59, 23.15)
Muscle/joint pain	25,835 (42.4%)	1,066 (23.9%)		i				21.54 (20.27, 22.99)
Reduced appetite	19,183 (31.4%)	639 (14.3%)		i I				19.05 (17.94, 20.13)
Reduced strength legs/arms	15,770 (25.9%)	431 (9.7%)		1	-	•-		17.33 (16.30, 18.28)
Hot flushes/sweat	21,220 (34.8%)	904 (20.2%)		1	-•	-		16.37 (14.87, 17.73)
Fatigue/exhaustion	28,779 (47.2%)	1,515 (33.9%)		1				14.39 (12.85, 16.00)
Dizziness	13,440 (22.0%)	452 (10.1%)		1	-			13.77 (12.78, 14.73)
Dyspnea	12,213 (20.0%)	370 (8.3%)		1	-			13.60 (12.62, 14.44)
Headache	26,880 (44.1%)	1,481 (33.2%)		i				11.59 (10.00, 13.16)
Chest pain	9,003 (14.8%)	279 (6.2%)		1	+			10.01 (9.19, 10.73)
Nausea	7,450 (12.2%)	320 (7.2%)		¦				6.41 (5.67, 7.25)
Sleeping legs/arms	5,524 (9.1%)	162 (3.6%)		i 🔸				6.19 (5.59, 6.75)
Diarrhoea	6,559 (10.8%)	301 (6.7%)						4.93 (4.17, 5.65)
Abdominal pain	5,103 (8.4%)	279 (6.2%)						3.17 (2.42, 3.87)
Red runny eyes	4,126 (6.8%)	208 (4.7%)		. .				2.70 (2.01, 3.35)
Cough	21,917 (35.9%)	1,772 (39.7%)						-1.79 (-3.39, -0.27)
Runny nose	15,654 (25.7%)	1,770 (39.6%)		1				-11.98 (-13.58, -10.22)
Sore throat	17,902 (29.3%)	2,183 (48.9%)		1				-16.93 (-18.51, -15.27)
		-20.0	-10.0	0.0	10.0	20.0	30.0	40.0

Note: "Around the test date" is defined as from one week prior to the test date and until four weeks after. For symptoms around the test date, test-negatives with symptoms as indication for testing are used as control population. Risk differences with 95% confidence intervals were adjusted for age, sex, comorbidities, obesity, healthcare-occupation and time after testing (in months).

Symptom	Hospitalized (n,%)	Non-hospitalized (n,%)	i.	Risk Difference (95% CI)
Fatigue/exhaustion	397 (16.4%)	6,402 (10.9%)		8.64 (6.70, 10.74)
Reduced strength legs/arms	302 (12.5%)	3,079 (5.3%)	-	7.13 (5.55, 8.66)
Dyspnea	274 (11.3%)	3,003 (5.1%)	· · · · · · · · · · · · · · · · · · ·	6.71 (5.17, 8.39)
Muscle/joint pain	201 (8.3%)	3,016 (5.1%)	_	5.05 (3.57, 6.72)
Headache	180 (7.4%)	3,560 (6.1%)	_	4.58 (2.86, 6.31)
Sleeping legs/arms	203 (8.4%)	2,638 (4.5%)		4.25 (2.87, 5.68)
Dizziness	158 (6.5%)	2,272 (3.9%)	¦	4.11 (2.64, 5.72)
Chest pain	121 (5.0%)	1,574 (2.7%)		4.02 (2.69, 5.38)
Cough	151 (6.2%)	2,805 (4.8%)		2.81 (1.45, 4.36)
Hot flushes/sweat	108 (4.5%)	1,939 (3.3%)	e	2.53 (1.34, 3.86)
Nausea	69 (2.9%)	1,110 (1.9%)	_	2.38 (1.24, 3.53)
Abdominal pain	71 (2.9%)	1,170 (2.0%)	· - • - · · · · · · · · · · · · · · · ·	1.88 (0.93, 2.87)
Reduced appetite	90 (3.7%)	1,682 (2.9%)	_	1.78 (0.63, 2.95)
Sore throat	95 (3.9%)	2,187 (3.7%)		1.52 (0.15, 2.80)
Fever	68 (2.8%)	1,294 (2.2%)		1.44 (0.43, 2.46)
Red runny eyes	58 (2.4%)	764 (1.3%)	_	1.41 (0.62, 2.32)
Chills	57 (2.4%)	909 (1.6%)	·	1.38 (0.53, 2.28)
Runny nose	92 (3.8%)	2,284 (3.9%)	·	1.15 (-0.12, 2.36)
Diarrhoea	57 (2.4%)	1,065 (1.8%)	_ _	0.98 (0.16, 1.79)
Dysgeusia	184 (7.6%)	5,181 (8.8%) -	•	0.97 (-0.65, 2.69)
Dysosmia	188 (7.8%)	6,486 (11.1%)	1	-0.52 (-2.27, 1.21)
			H 0.0 2.0 4.0 6.0 8.0 10.0 1	12.0

Figure S2: Risk differences of symptoms 6-12 months after test, comparing hospitalized and non-hospitalized SARS-CoV-2 test-positive participants.

Figure S3: Risk differences self-reported health problems with new onset from the test date and up to after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group




Figure S4: Risk differences self-reported diagnoses with new onset from the test date and up to after 6-12 months, comparing SARS-CoV-2 test-positive and testnegative participants, stratified by sex and age group

